Coronavirus disease 2019 (COVID-19): angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and cardiovascular disease.
Identifieur interne : 000248 ( Main/Exploration ); précédent : 000247; suivant : 000249Coronavirus disease 2019 (COVID-19): angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and cardiovascular disease.
Auteurs : Garry Lr Jennings [Australie]Source :
- The Medical journal of Australia [ 1326-5377 ] ; 2020.
Descripteurs français
- KwdFr :
- Antagonistes des récepteurs aux angiotensines (effets indésirables), Betacoronavirus (effets des médicaments et des substances chimiques), Effets secondaires indésirables des médicaments (virologie), Humains (MeSH), Infections à coronavirus (complications), Infections à coronavirus (virologie), Inhibiteurs de l'enzyme de conversion de l'angiotensine (effets indésirables), Maladies cardiovasculaires (traitement médicamenteux), Pandémies (MeSH), Pneumopathie virale (complications), Pneumopathie virale (virologie).
- MESH :
- effets des médicaments et des substances chimiques : Betacoronavirus.
- effets indésirables : Antagonistes des récepteurs aux angiotensines, Infections à coronavirus, Inhibiteurs de l'enzyme de conversion de l'angiotensine, Pneumopathie virale.
- traitement médicamenteux : Maladies cardiovasculaires.
- virologie : Effets secondaires indésirables des médicaments, Infections à coronavirus, Pneumopathie virale.
- Humains, Pandémies.
English descriptors
- KwdEn :
- Angiotensin Receptor Antagonists (adverse effects), Angiotensin-Converting Enzyme Inhibitors (adverse effects), Betacoronavirus (drug effects), Cardiovascular Diseases (drug therapy), Coronavirus Infections (complications), Coronavirus Infections (virology), Drug-Related Side Effects and Adverse Reactions (virology), Humans (MeSH), Pandemics (MeSH), Pneumonia, Viral (complications), Pneumonia, Viral (virology).
- MESH :
- chemical , adverse effects : Angiotensin Receptor Antagonists, Angiotensin-Converting Enzyme Inhibitors.
- complications : Coronavirus Infections, Pneumonia, Viral.
- drug effects : Betacoronavirus.
- drug therapy : Cardiovascular Diseases.
- virology : Coronavirus Infections, Drug-Related Side Effects and Adverse Reactions, Pneumonia, Viral.
- Humans, Pandemics.
DOI: 10.5694/mja2.50622
PubMed: 32441063
PubMed Central: PMC7280580
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Coronavirus disease 2019 (COVID-19): angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and cardiovascular disease.</title><author><name sortKey="Jennings, Garry Lr" sort="Jennings, Garry Lr" uniqKey="Jennings G" first="Garry Lr" last="Jennings">Garry Lr Jennings</name><affiliation wicri:level="4"><nlm:affiliation>University of Sydney, Sydney, NSW.</nlm:affiliation><orgName type="university">Université de Sydney</orgName><country>Australie</country><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation><affiliation><nlm:affiliation>Baker Heart and Diabetes Institute, Melbourne, VIC.</nlm:affiliation><wicri:noCountry code="subField">VIC</wicri:noCountry></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32441063</idno><idno type="pmid">32441063</idno><idno type="doi">10.5694/mja2.50622</idno><idno type="pmc">PMC7280580</idno><idno type="wicri:Area/Main/Corpus">000237</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000237</idno><idno type="wicri:Area/Main/Curation">000237</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000237</idno><idno type="wicri:Area/Main/Exploration">000237</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Coronavirus disease 2019 (COVID-19): angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and cardiovascular disease.</title><author><name sortKey="Jennings, Garry Lr" sort="Jennings, Garry Lr" uniqKey="Jennings G" first="Garry Lr" last="Jennings">Garry Lr Jennings</name><affiliation wicri:level="4"><nlm:affiliation>University of Sydney, Sydney, NSW.</nlm:affiliation><orgName type="university">Université de Sydney</orgName><country>Australie</country><placeName><settlement type="city">Sydney</settlement><region type="état">Nouvelle-Galles du Sud</region></placeName></affiliation><affiliation><nlm:affiliation>Baker Heart and Diabetes Institute, Melbourne, VIC.</nlm:affiliation><wicri:noCountry code="subField">VIC</wicri:noCountry></affiliation></author></analytic><series><title level="j">The Medical journal of Australia</title><idno type="eISSN">1326-5377</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Angiotensin Receptor Antagonists (adverse effects)</term><term>Angiotensin-Converting Enzyme Inhibitors (adverse effects)</term><term>Betacoronavirus (drug effects)</term><term>Cardiovascular Diseases (drug therapy)</term><term>Coronavirus Infections (complications)</term><term>Coronavirus Infections (virology)</term><term>Drug-Related Side Effects and Adverse Reactions (virology)</term><term>Humans (MeSH)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (complications)</term><term>Pneumonia, Viral (virology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antagonistes des récepteurs aux angiotensines (effets indésirables)</term><term>Betacoronavirus (effets des médicaments et des substances chimiques)</term><term>Effets secondaires indésirables des médicaments (virologie)</term><term>Humains (MeSH)</term><term>Infections à coronavirus (complications)</term><term>Infections à coronavirus (virologie)</term><term>Inhibiteurs de l'enzyme de conversion de l'angiotensine (effets indésirables)</term><term>Maladies cardiovasculaires (traitement médicamenteux)</term><term>Pandémies (MeSH)</term><term>Pneumopathie virale (complications)</term><term>Pneumopathie virale (virologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Angiotensin Receptor Antagonists</term><term>Angiotensin-Converting Enzyme Inhibitors</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Cardiovascular Diseases</term></keywords><keywords scheme="MESH" qualifier="effets des médicaments et des substances chimiques" xml:lang="fr"><term>Betacoronavirus</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Antagonistes des récepteurs aux angiotensines</term><term>Infections à coronavirus</term><term>Inhibiteurs de l'enzyme de conversion de l'angiotensine</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Maladies cardiovasculaires</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Effets secondaires indésirables des médicaments</term><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term><term>Drug-Related Side Effects and Adverse Reactions</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Pandemics</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Humains</term><term>Pandémies</term></keywords></textClass></profileDesc></teiHeader></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32441063</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>29</Day></DateCompleted><DateRevised><Year>2020</Year><Month>06</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1326-5377</ISSN><JournalIssue CitedMedium="Internet"><Volume>212</Volume><Issue>11</Issue><PubDate><Year>2020</Year><Month>06</Month></PubDate></JournalIssue><Title>The Medical journal of Australia</Title><ISOAbbreviation>Med. J. Aust.</ISOAbbreviation></Journal><ArticleTitle>Coronavirus disease 2019 (COVID-19): angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and cardiovascular disease.</ArticleTitle><Pagination><MedlinePgn>502-503.e1</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5694/mja2.50622</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jennings</LastName><ForeName>Garry Lr</ForeName><Initials>GL</Initials><AffiliationInfo><Affiliation>University of Sydney, Sydney, NSW.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Baker Heart and Diabetes Institute, Melbourne, VIC.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Med J Aust</MedlineTA><NlmUniqueID>0400714</NlmUniqueID><ISSNLinking>0025-729X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057911">Angiotensin Receptor Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000806">Angiotensin-Converting Enzyme Inhibitors</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C000657245">COVID-19</SupplMeshName><SupplMeshName Type="Organism" UI="C000656484">severe acute respiratory syndrome coronavirus 2</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D057911" MajorTopicYN="N">Angiotensin Receptor Antagonists</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000806" MajorTopicYN="N">Angiotensin-Converting Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="Y">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">COVID-1</Keyword><Keyword MajorTopicYN="Y">Hypertension</Keyword><Keyword MajorTopicYN="Y">Infectious diseases</Keyword><Keyword MajorTopicYN="Y">Respiratory tract infections</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32441063</ArticleId><ArticleId IdType="doi">10.5694/mja2.50622</ArticleId><ArticleId IdType="pmc">PMC7280580</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Public Health England. Emergency Department Syndromic Surveillance System: England - year 2020, week 13. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/877600/EDSSSBulletin2020wk13.pdf.pdf (viewed Apr 2020).</Citation></Reference><Reference><Citation>Thornton J. COVID-19: AE visits in England fall by 25% in week after lockdown. BMJ 2020; 369: m1401.</Citation></Reference><Reference><Citation>Metzler B, Siostrzonek P, Binder RK, et al. Decline of acute coronary syndrome admissions in Austria since the outbreak of COVID-19: the pandemic response causes cardiac collateral damage. Eur Heart J 2020; https://doi.org/10.1093/eurheartj/ehaa314. [Epub ahead of print]</Citation></Reference><Reference><Citation>Garcia S, Albaghdadi M, Meraj P, Schmidt C, Garberich R, Jaffer F, et al. Reduction in ST-segment elevation cardiac catheterization laboratory activations in the United States during COVID-19 pandemic. J Am Coll Cardiol 2020; https://doi.org/10.1016/j.jacc.2020.04.011. [Epub ahead of print]</Citation></Reference><Reference><Citation>Cohen B, Shaw D. Cardiac arrest deaths at home in New York City have increased by a startling 800%. Angioplasty.org 2020; 8 Apr. http://www.ptca.org/news/2020/0408_INCREASED_DEATHS_NYC.html (viewed Apr 2020).</Citation></Reference><Reference><Citation>National Heart Foundation of Australia. Guideline for the diagnosis and management of hypertension in adults, 2016. Melbourne: National Heart Foundation of Australia, 2016. https://www.heartfoundation.org.au/getmedia/c83511ab-835a-4fcf-96f5-88d770582ddc/PRO-167_Hypertension-guideline-2016_WEB.pdf (viewed Apr 2020).</Citation></Reference><Reference><Citation>NHFA CSANZ Heart Failure Guidelines Working Group; Atherton JJ, Sindone A, De Pasquale CG, et al. National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: guidelines for the prevention, detection, and management of heart failure in Australia. Heart Lung Circ 2018: 27, 1123-1208.</Citation></Reference><Reference><Citation>Sommerstein R, Gräni C. Rapid response: re: preventing a Covid-19 pandemic: ACE inhibitors as a potential risk factor for fatal Covid-1. BMJ 2020; 368: m810.</Citation></Reference><Reference><Citation>Esler M, Esler D. Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic? J Hypertens 2020; 38: 781-782.</Citation></Reference><Reference><Citation>Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA 2020; https://doi.org/10.1001/jama.2020.5394. [Epub ahead of print]</Citation></Reference><Reference><Citation>Gheblawia M, Wang K, Viveiros A, et al. Angiotensin converting enzyme 2: SARS-CoV-2 Receptor and regulator of the renin-angiotensin system. Circ Res 2020; https://doi.org/10.1161/circresaha.120.317015. [Epub ahead of print]</Citation></Reference><Reference><Citation>Ferrario CM, Jessup J, Gallagher PE, et al. Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors. Kidney Int 2005; 68: 2189-2196.</Citation></Reference><Reference><Citation>Patel SK, Velkoska E, Freeman M, et al. From gene to protein - experimental and clinical studies of ACE2 in blood pressure control and arterial hypertension. Front Physiol 2014; 5: 227.</Citation></Reference><Reference><Citation>Sparks MA, Hiremath S. The coronavirus conundrum: ACE2 and hypertension edition. NephJC 2020. http://www.nephjc.com/news/covidace2 (viewed Mar 2020).</Citation></Reference><Reference><Citation>Zaman S, MacIsaac AI, Jennings GLR, et al. Cardiovascular disease and COVID-19: Australian/New Zealand consensus statement [preprint]. Med J Aust 2020. https://www.mja.com.au/journal/2020/cardiovascular-disease-and-covid-19-australiannew-zealand-consensus-statement</Citation></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Australie</li></country><region><li>Nouvelle-Galles du Sud</li></region><settlement><li>Sydney</li></settlement><orgName><li>Université de Sydney</li></orgName></list><tree><country name="Australie"><region name="Nouvelle-Galles du Sud"><name sortKey="Jennings, Garry Lr" sort="Jennings, Garry Lr" uniqKey="Jennings G" first="Garry Lr" last="Jennings">Garry Lr Jennings</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CardioCovidV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000248 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000248 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CardioCovidV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32441063
|texte= Coronavirus disease 2019 (COVID-19): angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and cardiovascular disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32441063" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CardioCovidV1
| This area was generated with Dilib version V0.6.35. |  |